Jeffrey Kindler Sells 185,000 Shares of Precigen (NASDAQ:PGEN) Stock

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) Director Jeffrey Kindler sold 185,000 shares of Precigen stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director owned 17,100 shares of the company’s stock, valued at $127,224. This trade represents a 91.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Precigen Stock Performance

Shares of NASDAQ:PGEN opened at $6.95 on Friday. Precigen, Inc. has a 12-month low of $2.99 and a 12-month high of $7.72. The company’s 50 day moving average price is $6.05 and its two-hundred day moving average price is $4.75. The firm has a market cap of $2.48 billion, a PE ratio of -6.68 and a beta of 1.02. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15.

Get Precigen alerts:

Precigen (NASDAQ:PGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. The business had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm’s revenue for the quarter was up 6322.7% on a year-over-year basis. Equities research analysts predict that Precigen, Inc. will post 0.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PGEN. Wall Street Zen raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citigroup reissued an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 5th. Citizens Jmp upped their target price on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Precigen has a consensus rating of “Moderate Buy” and an average price target of $14.50.

View Our Latest Stock Report on PGEN

Institutional Investors Weigh In On Precigen

Large investors have recently modified their holdings of the company. Patient Capital Management LLC bought a new position in shares of Precigen in the 2nd quarter worth about $108,511,000. BlackRock Inc. bought a new stake in shares of Precigen during the 2nd quarter valued at about $97,737,000. State Street Corp grew its stake in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after purchasing an additional 6,335,033 shares during the period. Geode Capital Management LLC grew its stake in Precigen by 15.9% during the fourth quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock worth $18,653,000 after purchasing an additional 613,340 shares during the period. Finally, Occam Crest Management LP increased its holdings in Precigen by 29.6% in the fourth quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after purchasing an additional 799,339 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

Read More

• Five stocks we like better than Precigen
• From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
• These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
• Venture Into High-Volatility Corners of the Market With These 3 ETFs
• 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.